Clinical Trial: Study of EPI-001 in Patients With Androgenetic Alopecia

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07618195) titled 'Study of EPI-001 in Patients With Androgenetic Alopecia' on May 20.

Brief Summary: This is a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia.

In the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration.

In the Phase IIa portion, subjects will be randomized in a 2:1 ratio to receive either EPI-001 or placebo. Safety and efficacy will be evaluated through hair count as...